Sargent Investment Group LLC Sells 1,645 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Sargent Investment Group LLC decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 296,350 shares of the biotechnology company’s stock after selling 1,645 shares during the period. Exelixis makes up about 1.6% of Sargent Investment Group LLC’s investment portfolio, making the stock its 17th largest position. Sargent Investment Group LLC owned 0.10% of Exelixis worth $7,109,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Alaska Permanent Fund Corp increased its position in Exelixis by 1.5% during the third quarter. Alaska Permanent Fund Corp now owns 40,855 shares of the biotechnology company’s stock valued at $893,000 after acquiring an additional 596 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of Exelixis by 44.2% in the third quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 604 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Exelixis by 17.1% in the third quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 668 shares during the last quarter. Treasurer of the State of North Carolina grew its holdings in shares of Exelixis by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company’s stock worth $3,176,000 after purchasing an additional 738 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Exelixis by 0.5% in the fourth quarter. Jennison Associates LLC now owns 164,200 shares of the biotechnology company’s stock worth $3,939,000 after purchasing an additional 815 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a report on Wednesday, April 10th. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. Royal Bank of Canada upped their price objective on shares of Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Stifel Nicolaus upped their price objective on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Friday, February 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research note on Friday, January 26th. Six research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.29.

Insider Activity at Exelixis

In other Exelixis news, Director David Edward Johnson purchased 190,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were bought at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares in the company, valued at $22,785,111. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Patrick J. Haley sold 47,020 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the transaction, the executive vice president now owns 384,866 shares in the company, valued at approximately $8,255,375.70. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David Edward Johnson purchased 190,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was acquired at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares in the company, valued at approximately $22,785,111. The disclosure for this purchase can be found here. 2.90% of the stock is currently owned by insiders.

Exelixis Price Performance

Shares of EXEL stock traded up $0.17 during mid-day trading on Friday, hitting $23.70. 1,560,811 shares of the stock traded hands, compared to its average volume of 1,843,234. The stock has a market cap of $6.99 billion, a P/E ratio of 37.03, a P/E/G ratio of 0.61 and a beta of 0.54. The stock’s fifty day moving average is $22.80 and its two-hundred day moving average is $22.19. Exelixis, Inc. has a 52-week low of $18.08 and a 52-week high of $24.34.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.25 by $0.02. The firm had revenue of $479.65 million during the quarter, compared to analyst estimates of $481.23 million. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. As a group, equities analysts forecast that Exelixis, Inc. will post 1.23 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.